Cargando…
DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?
Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents. While various immune-based strategies can elicit anti-tumour responses, DNA vaccines present increased efficac...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502114/ https://www.ncbi.nlm.nih.gov/pubmed/23046944 http://dx.doi.org/10.1186/1479-0556-10-9 |